News

Further studies are needed to confirm the additional reductions in monthly headache days observed in patients with migraine who were treated with onabotulinumtoxinA and an add-on CGRP agent.

The $7.2 million grant will evaluate central vein sign as a biomarker for multiple sclerosis diagnosis.

Consistent pain relief from all attacks was reported by 27% of patients treated with ubrogepant and 73% experienced relief from at least 1 attack.

Preliminary 12-month data from the JEWELFISH study in previously treated patients showed rapid and sustained increases in survival motor neuron protein levels.

Impel NeuroPharma, the agent’s developer, is on target for submission of a new drug application for the treatment in the second half of 2020.

The device will now be available with prescription through Azova’s Collaborative Clinical Care Platform for those with migraine.

Emphasis on prevention of intracranial hemorrhage at an early stage is recommended to mitigate further risks later in a patient’s life, especially in older individuals.

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital spoke to the specific datasets she is anticipating at the AHS 2020 meeting.

In Part 1 of this interview, the clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research provides in-depth insight on his study evaluating masculinity norms in patients with multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 12, 2020.

Ahead of sessions kicking off on June 13, Jessica Ailani, MD, FAHS, offers a look into what data, plenary talks, and developments are set to be presented at the upcoming AHS 2020 annual meeting.

The treatment, marketed as Uplizna, is only the second approved therapy for NMOSD.

Despite the likelihood of women receiving IV thrombolysis still being 13% lower than men, the gap narrowed by 17% from 2008 to 2018 compared to what was observed from 2000 to 2008.

The clinical health psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic details the use of behavioral health and potential use of Conformity to Masculine Norms Inventory (CMNI) tool in multiple sclerosis care.

Effectively addressing vascular risk factors could provide an important avenue for modifying white matter hyperintensity disease burden.

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to the rapid expansion of headache medicine and what new research will be discussed at AHS 2020.

The new data from the phase 2 NURTURE study are set to be presented at the virtual Cure SMA Research and Clinical Care Meeting.

Results of the Jackson Heart Study suggest that cigarette smoking is linked with a dose-dependent higher risk of all stroke in black individuals compared to those who did not smoke.

An overwhelming number of patients with relapsing multiple sclerosis may accumulate disability due to underlying progressive disease course independent of relapse activity.